Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Nov 16, 2024Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and...
-
Nov 15, 2024
Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Axonics, Inc. (Nasdaq: AXNX), a medical technology company focused on the development and...
-
Oct 24, 2024Diagnostic algorithm shown to detect early signs of worsening heart failure and reduce hospitalisations for patients with cardiac implantable electronic devices
HEMEL HEMPSTEAD, United Kingdom, 24 October, 2024 – Boston Scientific (NYSE: BSX) announced that the National Institute for Health and Care Excellence (NICE), which provides evidence-based...
-
Sep 9, 2024Un sondaggio dimostra che depressione e stanchezza sono comuni tra le persone che vivono con il dolore cronico
MILANO, Italia, 9 Settembre 2024 – Il mese di settembre è dedicato alla sensibilizzazione sul dolore cronico, una condizione che colpisce più di 10 milioni di persone in Italia1. Boston...
-
Sep 9, 2024Befragung zeigt, dass junge Menschen in Folge chronischer Schmerzen mit Depressionen und Angstzuständen zu kämpfen haben.
Düsseldorf, Deutschland – 09. September 2024 – Eine neue Umfrage unter Menschen mit chronischen Schmerzen in Deutschland zeigt die teils deutlichen Auswirkungen chronischer Schmerzen auf die...
-
Sep 9, 2024Responses of 1,000 people with chronic pain in the UK reveal the far-reaching burden of chronic pain on mental health, with many feeling misunderstood
HEMEL HEMPSTEAD, United Kingdom – 9 September, 2024 – A new survey highlights the profound impact chronic pain has on the lives of people living in the UK, often severely affecting their...
Aug 27, 2024Boston Scientific Corporation (NYSE: BSX) today announced it has obtained CE mark for the ACURATE Prime™ Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology...
Jun 20, 2024Vercise™ Neural Navigator 5 con tecnologia STIMVIEW™ XT è progettato per semplificare la procedura per le persone affette da patologie neurologiche.HEMEL HEMPSTEAD, Regno Unito – Giovedì 20 giugno 2024 – Boston Scientific Corporation (NYSE: BSX) ha ottenuto il marchio CE per il software Vercise™ Neural Navigator 5 con tecnologia...
Jun 20, 2024Vercise™ Neural Navigator 5 con tecnología STIMVIEW™ XT está diseñado para agilizar el procedimiento para las personas que viven con afecciones neurológicasMadrid, 20 de junio de 2024 – Boston Scientific Corporation (NYSE: BSX) ha obtenido la aprobación del marcado CE para su Software Vercise™ Neural Navigator 5 con tecnología STIMVIEW™ XT....
- Jun 20, 2024Vercise™ Neural Navigator 5 mit STIMVIEW™ XT-Technologie soll das Verfahren für Menschen mit neurologischen Störungen vereinfachen
DÜSSELDORF – 20. Juni 2024 – Die Boston Scientific Corporation (NYSE: BSX) hat die CE-Kennzeichnung für die Vercise™ Neural Navigator 5 Software mit STIMVIEW™ XT Technologie erhalten,...
- Jun 20, 2024Vercise™ Neural Navigator 5 with STIMVIEW™ XT technology is designed to streamline procedure for people living with neurological conditions
HEMEL HEMPSTEAD, United Kingdom – 20 June 2024 – Boston Scientific Corporation (NYSE: BSX) has obtained CE Mark on the Vercise™ Neural Navigator 5 Software with STIMVIEW™ XT technology,...
-
Jan 8, 2024Acquisition to expand urology portfolio with differentiated technologies to treat urinary and bowel dysfunction
Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Axonics, Inc. (Nasdaq: AXNX), a publicly traded medical technology company primarily...
Dec 12, 2023El nuevo acuerdo de compra de energía virtual (VPPA, por sus siglas en inglés) contribuye a alcanzar las ambiciones de descarbonización de la compañía en su camino hacia cero emisionesMADRID, ESPAÑA, 12 de diciembre de 2023 – Boston Scientific Corporation (NYSE: BSX) ha activado su primer acuerdo europeo de compra de energía virtual (Virtual Power Purchasing Agreement en inglés) junto a BayWa r.e., empresa alemana líder en el desarrollo de energía renovable y proveedora de soluciones que impulsará a la compañía a cumplir sus objetivos de descarbonización.
- Dec 12, 2023New virtual power purchase agreement helps to advance the company’s decarbonisation goals on its path to net zero
MADRID, SPAIN, 12 December 2023 – Boston Scientific Corporation (NYSE: BSX) has activated its first European virtual power purchase agreement (VPPA) with leading renewable energy developer and solutions provider BayWa r.e., helping the company make progress on its decarbonisation targets.
-
Sep 5, 2023Viele Menschen mit chronischen Schmerzen sind laut Umfrage bereits in jungen Jahren betroffen und Frauen fühlen sich mit ihren Schmerzen vom Umfeld wenig verstanden.
Düsseldorf – 5. September 2023 – Boston Scientific veröffentlichte heute Ergebnisse einer repräsentativen Befragung von 1.000 Menschen mit chronischen Schmerzen, laut denen dieses Leiden in...
-
Sep 5, 2023Research conducted in the United Kingdom for pain awareness month points to a gender difference in the experience of chronic pain, pursuing pain relief and the feeling of being understood
HEMEL HEMPSTEAD, United Kingdom – 5 Sept. 2023 – Boston Scientific (NYSE: BSX) today revealed survey results of 2,000 people living with chronic pain in the United Kingdom (UK) that unveiled...
May 18, 2023Taoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in ClonmelTaoiseach Leo Varadkar joins company’s 25-year anniversary celebrations in Clonmel CLONMEL, IRELAND (19 May 2023) - Boston Scientific Corporation (NYSE: BSX) will today announce an €80 million...
-
Nov 29, 2022
Acquisition to expand endoluminal surgery portfolio and add differentiated technologies for endobariatric procedures MARLBOROUGH, Mass., Nov. 29, 2022 /PRNewswire/ -- Boston Scientific Corporation...
-
Nov 8, 2022El algoritmo de doble etapa detecta y verifica posibles arritmias cardíacas para ayudar a aumentar la eficiencia clínica
MADRID, 8 de noviembre de 2022 - Boston Scientific ha anunciado hoy, a la comunidad médico-científica especializada, el lanzamiento en Europa del Sistema de Monitor Cardíaco Insertable (MCI)...
-
Nov 8, 2022Zweistufiger Algorithmus erkennt und überprüft potenzielle Herzrhythmusstörungen, um klinische Wirksamkeit zu steigern
Düsseldorf, 8. November 2022 – Die Boston Scientific Corporation (NYSE: BSX) gab heute die Markteinführung des LUX-Dx Insertable Cardiac Monitor (ICM) Systems in Europa bekannt. Das...
-
Nov 8, 2022Algoritmo a doppia fase per verificare potenziali aritmie cardiache
Milano, 8 novembre 2022 - Boston Scientific Corporation (NYSE: BSX) ha annunciato oggi l’introduzione in Europa del nuovo monitor cardiaco inseribile LUX-Dx™ (ICM), un dispositivo diagnostico...
-
Nov 8, 2022Dual-stage algorithm detects and verifies potential heart arrhythmias to help increase clinical efficiency
LONDON, November 8, 2022 – Boston Scientific Corporation (NYSE: BSX) today announced the European launch of the LUX-Dx™ Insertable Cardiac Monitor (ICM) System, a long-term diagnostic device...
Jun 21, 2022Ripristinare funzioni vitali e qualità di vita dopo l’asportazione di un tumore alla prostata: le opzioni terapeutiche risolutive e sostenibili per l’incontinenza urinaria maschile Milano, 21...
Apr 14, 2022Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming yearsBOSTON SCIENTIFIC ANNOUNCES €100M INVESTMENT IN GALWAY CAMPUS Taoiseach Micheál Martin welcomes new expansion that is expected to enable 300+ jobs in coming years GALWAY, IRELAND (14 April...
-
Apr 4, 2022More UK patients with Benign Prostatic Enlargement (BPE) should now have improved access to these treatments thanks to inclusion in medtech funding pathway
HEMEL HEMPSTEAD, UK., Mon 4 April, 2022– Boston Scientific Corporation (NYSE: BSX) is pleased to announce the inclusion of two innovative devices in this year’s NHS MedTech Funding Mandate...
-
Feb 15, 2022
MARLBOROUGH, Mass., 15. Februar 2022– Boston Scientific Corporation (NYSE: BSX) hat heute den Abschluss seiner Übernahme von Baylis Medical Company Inc. bekannt gegeben, einem Unternehmen, das...
-
Feb 15, 2022
MARLBOROUGH, Mass., February 15, 2022– Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced...
-
Dec 8, 2021Trial studying communication between cardiac rhythm management devices aims to expand treatment options for patients who require an ICD
Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™ Modular Therapy System. The mCRM System...
-
Oct 6, 2021Late-breaking data demonstrate superior rates of primary patency and statistically significant sustained clinical improvement
Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) during a late-breaking clinical trial presentation at...
-
Oct 5, 2021Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21Analysis found no intracerebral hemorrhages, low major bleeding rates; registry represents largest data set in interventional treatment of pulmonary embolism
Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular...
-
Oct 5, 2021Two-year data demonstrate continued high rates of primary patency including in patients with complex lesions
Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical trial presentation at the Vascular InterVentional...
Sep 29, 2021Investment earmarked for new technology capabilities and jobs growthCORK (29 September 2021) – Boston Scientific Corporation (NYSE: BSX) today announced a €30 million investment in its Cork facility to accelerate the development and manufacturing of...
-
Sep 20, 2021EPOCH trial represents the first positive phase 3 study for selective internal radiation therapy
MARLBOROUGH, Mass. (September 20, 2021) – Boston Scientific Corporation (NYSE: BSX) announced the EPOCH clinical trial of the TheraSphere™ Y-90 Glass Microspheres (TheraSphere treatment)...
-
Sep 2, 2021Terapia sin parestesias de acción rápida clínicamente probada que demuestra un alivio del dolor importante y sostenido en cuestión de minutos
MARLBOROUGH, Mass., 2 de septiembre, 2021- Boston Scientific (NYSE: BSX) anunció hoy el lanzamiento en Europa de la terapia FAST para sus sistemas de estimulación de la médula espinal (SCS)...
-
Sep 2, 2021Fast-Acting Sub-perception Therapy (FAST) clinically proven to demonstrate significant and sustained pain relief within minutes
MARLBOROUGH, Mass., September 2, 2021 – Boston Scientific (NYSE: BSX) today announced the European launch of FAST Therapy for its WaveWriter Alpha Spinal Cord Stimulator (SCS) Systems. The new...
-
Sep 2, 2021Schnell wirkende, klinisch erprobte Sub-Wahrnehmungstherapie, die eine deutliche und dauerhafte Schmerzlinderung innerhalb von Minuten bewirkt
MARLBOROUGH, Mass., 2. September 2021 – Boston Scientific (NYSE: BSX) verkündete heute die Markteinführung von FAST für seine WaveWriter Alpha Rückenmarkstimulations-Systeme (SCS-Systeme) in...
-
Aug 29, 2021
MARLBOROUGH, Mass., DATE, 2021– Boston Scientific (NYSE: BSX) today announced the close of its acquisition of the global surgical business of Lumenis LTD., a privately-held company that develops...
-
Aug 4, 2021Boston Scientific startet randomisierte, kontrollierte Studie für das endovaskuläre System EkoSonic©Studie vergleicht erstmals interventionelle Therapie in Kombination mit Antikoagulation mit Antikoagulation allein zur Behandlung von Lungenembolie
MARLBOROUGH, Mass. (04. August 2021) - Die Boston Scientific Corporation (NYSE: BSX) hat mit der Rekrutierung für die klinische Studie HI-PEITHO begonnen, eine gemeinschaftliche Forschungsstudie...
-
Aug 4, 2021Study is first to compare interventional therapy in combination with anticoagulation to anticoagulation alone for treatment of pulmonary embolism
Boston Scientific Initiates Randomized Controlled Trial for the EkoSonic™ Endovascular System Study is first to compare interventional therapy in combination with anticoagulation to...
-
Jun 24, 2021Acquisition complements company's electrophysiology portfolio to include the only commercially available cardiac pulsed field ablation technology
Boston Scientific Corporation (NYSE: BSX) today announced it exercised its option to acquire the remaining shares of Farapulse, Inc. The acquisition will complement the existing Boston Scientific...
-
Jun 24, 2021Una patologia sottovalutata e aggravata da reticenze e tabù – ma le soluzioni ci sono Dal 21 al 27 giugno la “World Continence Week
Incontinenza urinaria: un dramma nascosto e un problema sociale per 5 milioni di italiani Una patologia sottovalutata e aggravata da reticenze e tabù – ma le soluzioni ci sono Dal 21 al 27...
Jun 23, 2021En el Mes de la Salud Masculina, los expertos señalan que los hombres son reacios a hablar sobre sus preocupaciones urinarias y sexuales porque se han erigido multitud de mitos y tópicos, pero existen soluciones y los pacientes merecen conocerlas.Madrid, 17 de junio de 2021. En España, el cáncer de próstata es el de mayor incidencia en varones (por encima de pulmón y colon) con más de 30.000 casos al año.4 La posibilidad de...
-
Jun 9, 2021Der neue strahlenundurchlässige Hydrogel-Abstandhalter ist im CT-Scan sichtbar und bietet eine bessere Behandlungsoption für Ärzte bei der Strahlentherapie von Patienten mit Prostatakrebs
Boston Scientific Führt Spaceoar Vue™ Hydrogel Auf
Dem Europäischen Markt Ein Der neue strahlenundurchlässige Hydrogel-Abstandhalter ist im CT-Scan sichtbar und bietet eine bessere... 
Jun 9, 2021El nuevo espaciador de hidrogel radiopaco es visible en el TAC, una opción mejorada para los médicos que tratan a pacientes con cáncer de próstata sometidos a radioterapiaBoston Scientific Inicia el Lanzamiento Europeo del Hidrogel Spaceoar Vue™ El nuevo espaciador de hidrogel radiopaco es visible en el TAC, una opción mejorada para los médicos que tratan a...
Jun 9, 2021The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing Radiation for Prostate CancerBoston Scientific Initiates European Launch of Spaceoar Vue™ Hydrogel The New Radiopaque Hydrogel Spacer is Visible on CT Scan, an Enhanced Option for Physicians Treating Patients Undergoing...
-
May 25, 2021L'azienda inizierà il rilascio limitato sul mercato europeo a giugno
Boston Scientific ottiene il marchio CE per il broncoscopio monouso EXALT™ Model B L'azienda inizierà il rilascio limitato sul mercato europeo a giugno MARLBOROUGH (Massachusetts), 25 maggio...
-
May 25, 2021Company to begin limited market release in Europe in June
Boston Scientific Completes CE Mark for EXALT™ Model B Single-Use Bronchoscope Company to begin limited market release in Europe in June MARLBOROUGH, Mass., May 25 2021 -- Boston Scientific...
-
May 25, 2021La empresa iniciará la comercialización limitada en Europa en junio
Boston Scientific completa el proceso de obtención del marcado CE para el broncoscopio de un solo uso EXALT™ Model B La empresa iniciará la comercialización limitada en Europa en junio...
May 25, 2021Das Unternehmen startet die limitierte Markteinführung in Europa im JuniBoston Scientific erhält das CE-Zeichen für das EXALT™ Model B Bronchoskop zum Einmalgebrauch Das Unternehmen startet die limitierte Markteinführung in Europa im Juni MARLBOROUGH, Mass., 25...